UK Freephone Orders
0800 387732
9am to 5pm Mon-Fri
International Orders
+44 2380 487209
Select Your Country

Calprotectin ELISA

The BÜHLMANN fCAL® ELISA (EK-CAL) is the UK market-leading calprotectin ELISA. It provides quantitative in vitro determination of faecal calprotectin in high sample throughput environments.

The kit format is a microtitre plate based assay that can be performed manually or on an automated ELISA system to reduce hands-on time.
CE marked protocols are available for the Dynex DS2 and DSx plus the Grifols Triturus®.
Alpha Laboratories Ltd. supplies the Dynex DS2 for capital purchase or reagent rental.

Two different protocols are available with the fCAL ELISA to cover the ranges required for IBD and IBS differentiation plus the extended range format for use in monitoring patient therapy and mucosal healing. This reduces the need for further dilution and repeated assay.
The ranges are 10-600µg/g or 30-1800µg/g.
A consistent cut-off of 50µg/g is used throughout the Bühlmann Calprotectin range.

Simple extraction procedures for Calprotectin are available using the dedicated CALEX® Cap device or the Schebo or Roche extraction devices. 

All reagents, standards and controls are provided in one kit and are ready for use.
There is no requirement for reconstituting any component, apart from the wash buffer.
This minimizes any errors as well as ensuring a long shelf life.

  • Easy-to-use ELISA kit (total assay time is 75 minutes)
  • All reagents are ready to use*
  • Kit includes calibrators and controls
  • Analytical Sensitivity: <10µg/g Calprotectin in faecal sample
  • Established cut-off of 50µg/g
  • Measurable range 30-1800µg/g or 10-600µg/g**

* except wash buffer
** depending on which protocol is used

  • Calprotectin Revolution and Evolution

    • PDF size: 12.37KB
    • Uploaded on: 17/03/2017

    Open File
  • Converting from Quantum Blue to ELISA - Verification of Calprotectin ELISA Data

    • PDF size: 11.03KB
    • Uploaded on: 27/01/2017

    Open File
  • Diagnostics for Digestive Health Management

    • PDF size: 10.67KB
    • Uploaded on: 04/05/2017

    Open File
  • Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study

    • PDF size: 8.64KB
    • Uploaded on: 05/07/2016

    Turvill J et al., Department of Gastroenterology, York Teaching Hospital NHS Foundation Trust, Online First 2016

    Open File
  • False Positive Calprotectin User Report

    • PDF size: 14.05KB
    • Uploaded on: 08/11/2016

    User Report Published in Leading Edge - Autumn 2016

    Open File
  • fCAL® ELISA Flyer

    • PDF size: 8.86KB
    • Uploaded on: 03/05/2017

    Screening of Organic vs. Functional Disease and Therapy Follow-Up

    Open File

Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study
James Turvill, Assad Aghahoseini, Nala Sivarajasingham, Kazim Abbas, Murtaza Choudhry, Kostantinos Polyzois, Kostantinos Lasithiotakis, Dimitra Volanaki, Baek Kim, Fiona Langlands, Helen Andrew, Jesper Roos, Samantha Mellen, Daniel Turnock and Alison Jones
BJGP 

Emily K. Wright, MD, Michael A. Kamm, MD, PhD, Peter De Cruz, MD, PhD, Amy L. Hamilton, BSc, Kathryn J. Ritchie, BN, Jacqueline I. Keenan, PhD, Steven Leach, PhD, Laura Burgess, MSc, Alan Aitchison, BSc, Alexandra Gorelik, MSc, Danny Liew, MD, PhD, Andrew S. Day, MD, PhD, and Richard B. Gearry, MD, PhD
Inflamm Bowel Dis  Volume 22, Number 5, May 2016

FC appeared to be the optimal marker for identification of endoscopic postoperative recurrence, with high sensitivity and NPV. FC measurement is sufficiently sensitive in the postoperative setting after resection of all macroscopic disease to monitor for CD recurrence”.

 

Set Descending Direction

3 Item(s)

Grid List
Set Descending Direction

3 Item(s)

Grid List